Main content area

Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients

Fischer, Johannes C., Niederacher, Dieter, Topp, Stefan A., Honisch, Ellen, Schumacher, Sarah, Schmitz, Norma, Zacarias Föhrding, Luisa, Vay, Christian, Hoffmann, Imke, Kasprowicz, Nikola S., Hepp, Philip G., Mohrmann, Svjetlana, Nitz, Ulrike, Stresemann, Antje, Krahn, Thomas, Henze, Tanja, Griebsch, Evelyn, Raba, Katharina, Rox, Jutta M., Wenzel, Folker, Sproll, Christoph, Janni, Wolfgang, Fehm, Tanja, Klein, Christoph A., Knoefel, Wolfram Trudo, Stoecklein, Nikolas H.
Proceedings of the National Academy of Sciences of the United States of America 2013 v.110 no.41 pp. 16580-16585
biomarkers, biopsy, breast neoplasms, molecular genetics, monitoring, mononuclear leukocytes, neoplasm cells, patients, prediction
Circulating tumor cells (CTCs) are promising biomarkers for diagnosis and therapy in systemic cancer. However, their infrequent and unreliable detection, especially in nonmetastatic cancer, currently impedes the clinical use of CTCs. Because leukapheresis (LA) targets peripheral blood mononuclear cells, which have a similar density to CTCs, and usually involves processing the whole circulating blood, we tested whether LA could substantially increase CTC detection in operable cancer patients. Therefore, we screened LA products generated from up to 25 L of blood per patient in two independent studies, and found that CTCs can be detected in more than 90% of nonmetastatic breast cancer patients. Interestingly, complete white blood cell sampling enabled determining an upper level for total CTC numbers of about 100,000 cells (median, 7,500 CTCs) per patient and identified a correlation of CTC numbers with anatomic disease spread. We further show that diagnostic leukapheresis can be easily combined with the US Food and Drug Administration-approved CellSearch system for standardized enumeration of CTCs. Direct comparison with 7.5 mL of blood revealed a significantly higher CTC frequency in matched LA samples. Finally, genomic single-cell profiling disclosed highly aberrant CTCs as therapy-escaping variants in breast cancer. In conclusion, LA is a clinically safe method that enabled a reliable detection of CTCs at high frequency even in nonmetastatic cancer patients, and might facilitate the routine clinical use of CTCs as in the sense of a liquid biopsy. Combined with technologies for single-cell molecular genetics or cell biology, it may significantly improve prediction of therapy response and monitoring of early systemic cancer.